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Abstract
Objectives—To conduct psychometric analyses to (1) condense the Hot Flash Related Daily 
Interference Scale (HFRDIS) into a shorter form termed the Hot Flash Interference (HFI) scale, 
(2) evaluate cutpoints for both scales, and (3) establish minimally important differences (MIDs) 
for both scales.
Methods—We analyzed baseline and post-randomization patient-reported data pooled across 
three randomized trials aimed at reducing vasomotor symptoms (VMS) in 899 midlife women. 
Trials were conducted across five MsFLASH clinical sites between July 2009 and October 2012. 
We eliminated HFRDIS items based on experts’ content validity ratings and confirmatory factor 
analysis and evaluated cutpoints and established MIDs by mapping HFRDIS and HFI to other 
measures.
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Results—The 3-item HFI (interference with sleep, mood, and concentration) demonstrated 
strong internal consistency (alphas of 0.830 and 0.856), showed good fit to the unidimensional 
“hot flash interference factor”, and strong convergent validity with HFRDIS scores, diary VMS, 
and menopausal quality of life. For both scales, cutpoints of mild (0–3.9), moderate (4–6.9), and 
severe (7–10) interference were associated with increasing diary VMS ratings, sleep, and anxiety. 
The average MID was 1.66 for the HFRDIS and 2.34 for the HFI.
Conclusions—The HFI is a brief assessment of VMS interference and will be useful in busy 
clinics to standardize VMS assessment or in research studies where response burden may be an 
issue. The scale cutpoints and MIDs should prove useful in targeting those most in need of 
treatment, monitoring treatment response, and interpreting existing and future research findings.
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INTRODUCTION
The Hot Flash Related Daily Interference scale (HFRDIS) is a widely used, 
psychometrically sound, 10-item, self-report questionnaire assessing the impact of hot 
flashes on a woman’s life.1 The scale was introduced in 2001 to capture a symptom 
dimension (interference) that had not been previously considered in vasomotor symptom 
research because there were no assessment tools.1 The scale was based on similar pain 
interference2 and fatigue interference3 measures.1 Since publication, the HFRDIS has been 
translated to 12 languages, cited over 175 times in journal articles and textbooks, and was 
included as an outcome measure within the National Cancer Institute Physician Data Query 
Cancer Information Summaries for Supportive and Palliative Care (Coping with Cancer).4 
The HFRDIS is psychometrically strong with demonstrated responsiveness to interventions 
such as pharmacologic treatments, dietary supplements, and behavioral therapies.5–9
Interpretation of HFRDIS scores in research and clinical practice is limited by a lack of 
investigation in two areas. Cutpoints delineating mild, moderate, and severe interference and 
a minimally important difference (MID) have never been evaluated. A MID is “the smallest 
difference in score in the domain of interest that patients perceived as important, either 
beneficial or harmful, and that would lead the clinician to consider a change in the patient’s 
management” (p. 377).10
In addition, although the scale has only 10 items, a shorter scale could be more useful in 
busy clinical practices or in research where the HFRDIS is one of many measures to be 
completed by participants. Anecdotally, in using the scale over the past 15 years, the first 
author has noticed a pattern to women’s responses where a few items are more likely to be 
rated as zero or no interference, suggesting they may not be important items. Thus, there 
may be potential to create a shorter scale. According to psychometric theory, short form 
scales can be developed through psychometric testing and can perform equally well as the 
longer scales from which they are derived.11 Gaining expert opinion on the content validity 
of items, and performing psychometric analyses of women’s responses to the scale could 
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help identify the most salient items to retain in a shorter version of the scale. Such analyses 
have not been reported.
Therefore, given the widespread use yet limited knowledge of HFRDIS cutpoints and MIDs 
and the desire to create a shorter scale, we conducted psychometric analyses to (1) condense 
the HFRDIS into a shorter Hot Flash Interference (HFI) scale, (2) establish cutpoints for 
both scales, and (3) establish MIDs for both scales.
METHODS
Design
This was an analysis of baseline and post-randomization data from 899 peri- and post-
menopausal community-dwelling women who participated in MsFLASH trials 01, 02, and 
03. The three MsFLASH studies used standardized methods.12, 13 Common to all studies 
was a minimum eligibility criterion of 14 hot flashes per week. All studies were approved by 
the Institutional Review Boards at clinical sites and the Data Coordinating Center (DCC). 
Participants provided written informed consent and authorization to use protected health 
information.14–18
MsFLASH 01 was a randomized, placebo-controlled, double-blind trial of escitalopram 10 
mg/day or placebo for 8 weeks.14 If a reduction in VMS frequency of ≥ 50% or a decrease in 
VMS severity after 4 treatment weeks was not achieved, the dose was increased to 20 
mg/day (or matched placebo) without revealing the randomization. Approximately equal 
numbers of African-American and White women were enrolled. Baseline and 8-week post-
randomization data were used in this analysis.
MsFLASH 02 was a 3×2 factorial, randomized, controlled trial.15–17 We randomized 
eligible participants in a 3:3:4 ratio to 12 weeks of yoga, exercise, or usual activity, and 
simultaneously randomized in a 1:1 ratio to 1.8 g/day of omega-3 fatty acid or placebo. The 
omega-3 component of the trial was double-blinded.15 Baseline and 12-week post-
randomization data were used in this analysis.
MsFLASH 03 was a randomized, placebo-controlled, double blind, 8-week trial of low-dose 
oral 17-beta-estradiol 0.5 mg/day, venlafaxine XR (37.5 mg/day the first week, then 75 mg/
day), or placebo in a 2:2:3 ratio.18 Baseline and 8-week post-randomization data were used 
in this analysis.
Setting and Participants
Participants were recruited from July 2009 to October 2012, primarily by mass mailings to 
age-eligible women using purchased mailing lists and health-plan enrollment files. Common 
inclusion criteria for all trials included: women aged 40-62 years, in the menopause 
transition (amenorrhea ≥ 60 days in the past year), or postmenopausal (≥ 12 months since 
last menstrual period or bi-lateral oophorectomy), or had a hysterectomy with one or both 
ovaries remaining and FSH > 20 mIU/mL and estradiol ≤ 50 pg/mL, and in general good 
health as determined by medical history, physical exam, and blood tests. Hot flashes had to 
be rated as bothersome or severe on at least 4 days or nights per week, and the frequency in 
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screening week 3 could not decrease > 50% from the mean weekly levels in screening weeks 
1 and 2. Common exclusion criteria were: use of prescription or over-the-counter treatments 
for hot flashes (past 30 days), use of hormones or hormonal contraceptives (past 2 months), 
pregnancy or breastfeeding, any current severe or unstable medical conditions, drug or 
alcohol abuse (past year), history of myocardial infarction, angina or cerebrovascular events, 
or a major depressive episode (past 3 months).
Procedures
Interested women completed telephone screening and if eligible, completed a 2-week VMS 
diary and questionnaire with more detailed screening questions. Those who remained 
eligible completed a clinic visit for baseline assessment. They continued with the diary and 
completed a second clinic visit to confirm eligibility (second baseline visit) and complete 
randomization. To encourage protocol adherence and assess adverse events, telephone calls 
were made one or two weeks after randomization, and then again midway through the 
intervention periods. Follow-up clinic visits were conducted at midpoint and end of study: 4 
and 8 weeks post-randomization (MsFLASH 01 and 03) or 6 and 12 weeks post-
randomization (MsFLASH 02).
Measures
Baseline demographic characteristics collected from all women included age, race, ethnicity, 
menopausal status, education, and income. Height and weight were assessed by study staff 
in clinics for calculating body mass index.
VMS frequency, severity, and bother were collected in the morning and at bedtime on a 
paper-based daily diary. Ratings of severity were 0 (mild) to 2 (severe) and of bother were 0 
(not at all) to 3 (a lot). Ratings were used to calculate daytime, nighttime, and total VMS 
frequency, severity, and bother. Higher scores indicated worse outcomes.
The following measures were completed at a baseline clinic visit pre-randomization and 
again post-randomization (8 weeks for MsFLASH 01 and 03; 12 weeks for MsFLASH 02): 
the HFRDIS, Menopause Quality of Life Scale (MENQOL), two sleep measures (Pittsburgh 
Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI), and the Generalized Anxiety 
Disorders-7 (GAD-7) questionnaire.
The 10-item HFRDIS measures how much hot flashes have interfered with the following 10 
aspects of life in the past week: interference with work, social activities, leisure activities, 
sleep, mood, concentration, relations with others, sexuality, enjoyment of life, and life 
satisfaction. Each item is rated from 0 (none) to 10 (extremely). Responses were averaged to 
range from 0 to 10 with higher scores indicating greater interference (worse outcomes).
The 29-item MENQOL19 assesses menopause-related quality-of-life over the past 4 weeks. 
The scale has four domains (vasomotor, physical, psychosocial, and sexual). Subscores on 
each domain range from 1 (none) to 8 (worst) quality of life. Total MENQOL scores are 
calculated as the average of the 4 domain subscores. The MENQOL has good internal 
consistency (Cronbach’s alpha of 0.81 to 0.87 for each domain), adequate test-retest 
reliability, good validity, and demonstrated sensitivity to change with treatment.20
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The 19-item PSQI assesses global sleep as well as 7 components of sleep over the past 4 
weeks: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep 
disturbance, use of sleep medications, and daytime dysfunction.21, 22 Items use varying 
response categories and scores are calculated using a computational algorithm. Global scores 
greater than 5.0 are indicative of poor sleep quality and high sleep disturbances, and global 
scores ≥ 8 have been linked also to fatigue.23 Studies have documented one, two, and three 
factor structures for the PSQI, with a three factor model best representing sleep in midlife 
women with hot flashes.24 The scale has demonstrated sensitivity to detect changes in sleep 
during treatment for primary insomnia25 and sleep problems concurrent with vasomotor 
symptoms.5
The 7-item ISI assesses insomnia severity over the past 2 weeks. Participants rate each item 
on a 0 to 4 point scale (totals range from 0 to 28). Cutpoint scores for severity of insomnia 
are none (0–7), subthreshold (8–14), moderate (15–21), and severe (22–28).26 The ISI has 
the following psychometric properties: (1) good internal consistency with Cronbach’s alphas 
≥ 0.90 in people with and without insomnia;26 (2) concurrent validity with measures of 
fatigue, quality of life, and mood;26 and (3) responsiveness to treatments for primary 
insomnia26 and insomnia concurrent with vasomotor symptoms.27
The GAD-7 is a 7-item screening and severity measure validated for the four most common 
anxiety disorders in primary care: generalized anxiety, panic, social anxiety, and 
posttraumatic stress disorder. Responses to each item are for the past 2 weeks and range 
from 0 (not at all) to 4 (extremely) with total scores of 0 to 21. Reliability and validity have 
been established among more than 2700 general medical outpatients.28 GAD-7 cutpoints of 
5, 10, and 15 represent mild, moderate, and severe anxiety symptoms, respectively.28, 29
Statistical Analysis
Demographics were compared across the three trials using Pearson’s chi-squared and 
Kruskal-Wallis tests as appropriate.
Condensing the Scale—Following recommendations that five to ten experts rate items 
for content validity,30 we had seven menopause experts holding MD or PhD degrees and 
actively involved in menopause research and/or menopause clinical practice rate each 
HFRDIS item as: a) essential, b) useful but not essential, or c) not necessary. Ratings were 
done based on their own expertise and experience without knowledge of participants’ ratings 
or scores. We then calculated the content validity ratio (CVR) for each item and selected 
items to retain in the shorter scale based on a CVR cutpoint value ≥ 0.622.31 CVRs range 
from −1 (none of the experts rated the item as essential) to 1 (all of the experts rated the item 
as essential), with 0 indicating that 50% of the experts rated the item as essential. A CVR of 
0.622 corresponded to seven experts and a one-sided test of the null hypotheses that ≤ 50% 
of the experts would rate the item as essential at an alpha level of 0.05.31 Any item below 
this cutpoint was removed. We also examined item distributions. Total scores on both the 
HFRDIS and HFI were calculated as the average of the items. Since the possible response 
range for each item was 0 to 10, the average total score on both scales had a possible range 
of 0 to 10.
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We conducted several analyses to evaluate the shortened scale. First, we calculated 
Cronbach’s alphas for the full and shortened scales using data from the total cohort and each 
trial at baseline and post-randomization.
Next and because the HFI was conceptualized as measuring a single hot flash interference 
construct, we sought to verify that a one-factor model showed good fit to the original 10-
item HFRDIS data. To assess the fit of the unidimensional hot flash interference construct 
on the data we performed four confirmatory factor analyses based on unweighted least 
squares estimation of the model parameters: total sample and the three trial samples. Good 
fit of the models was defined as a Comparative Fit Index > 0.95 and a Tucker-Lewis Fit 
Index > 0.95.32 We also assessed Standardized Root Mean Square Residual, a reverse 
measure of fit with a value of 0 indicating perfect fit and values < 0.08 indicating good fit.32
Third, we correlated the full and shortened scales with one another, diary outcomes, and 
MENQOL scores at each time point using data from the total cohort. These associations 
were estimated using the nonparametric Spearman’s rank correlation coefficient 
(Spearman’s rho).
Evaluating Cutpoints—We used a theoretically driven approach to evaluate cutpoints for 
the HFRDIS and HFI in relation to other menopausal symptoms. We applied numeric 
bounds of mild (0–3.9), moderate (4–6.9) and severe (7–10). We then compared VMS diary, 
sleep and anxiety scores among the mild, moderate, and severe HFRDIS groups and among 
the mild, moderate, and severe HFI groups. For diary ratings, we used Kruskall-Wallis tests. 
For sleep and anxiety we used Kendall’s tau coefficients.
The numeric bounds were based on the authors’ experiences with how 0-10 point numeric 
rating scales are commonly interpreted in clinical practice and the only published study of 
symptom interference cutpoints we could locate.33 That study also used symptom severity 
ratings to establish interference cutpoints. Our theoretically driven approach is advantageous 
over a data driven approach for two reasons. First, it is less dependent on the idiosyncrasies 
of a particular sample and distribution of data within that sample. Second, it ensures there 
are common rather than unique numeric bounds across different symptoms or symptom 
dimensions. Data-driven approaches to establishing severity and interference cutpoints have 
resulted in equivocal findings across samples and across symptoms.34–37 Using common 
cutpoints ensures easier translation into practice.
Establishing MIDs—We calculated HFRDIS and HFI MIDs using anchor-based methods. 
First, we defined the MID as the mean change in these scales from baseline to post-
randomization (8 or 12 weeks) for women who reported a 40%-60% reduction in VMS 
frequency during a trial. We used this cutpoint because a 50% reduction in hot flashes has 
been suggested as the minimally clinically important difference.5, 38 We chose ± 10% as a 
reasonable boundary to ensure there was an adequate sample size of women for the MID 
analyses. Second, we calculated the MID as the mean change in scores for those that 
reported a 0.5 to 1.5 decrease in MENQOL total score, which is equal to the percent 
changing one or more response categories within a domain. We also conducted post hoc 
analyses to calculate the MID as the median change in scores and found similar results (i.e. 
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MIDs within 0.25 points of those found in the mean analysis). Results confirmed the mean 
analysis was not influenced by outliers or skewness, thus, only the mean MID analysis 
results are presented.
Sample Size Justification and Software—We evaluated statistical power post hoc 
using our available sample and our main hypothesis of a one-factor model for the HFRDIS. 
Power in confirmatory factor analysis using structural equation modeling is still a 
developing area of inquiry, so sample size guidelines are based on expert recommendations 
in two areas. First, for testing overall fit of a model, experts recommend a minimum sample 
size of 20039 which we exceeded with our overall sample size (N = 899) and each of our 
subsamples (n = 205, n = 355, n = 339). Second, for accurately estimating model 
parameters, Jackson40 recommends using an optimal participant to parameter ratio of 20:1, 
although ratios as low as 5:1 are considered acceptable.41 With a 10-item scale modeled as 1 
factor, there are 20 parameters being estimated (e.g., 1 factor loading plus 1 residual/error 
parameter per item). Thus, the participant to parameter ratio for the HFRDIS in our study 
was 45:1 for the overall sample, and > 10:1 for each of the subsamples.
All statistical analyses except for the confirmatory factor analysis were performed using 
STATA 14 for Windows. The lavaan42 statistical package in R was used for the confirmatory 
factor analyses.
RESULTS
Demographics of the 899 participants in the three trials are shown in Table 1. Most 
participants were in their middle 50’s, White or African-American, educated beyond high 
school, never smokers, overweight or obese, and postmenopausal. In all trials, median VMS 
frequency at baseline was more than 6 per day with moderate severity and bother, and 
median hot flash interference was around 3.
Condensed Scale
Shown in Table 2 are the experts’ CVRs and participants’ pooled descriptive data by 
HFRDIS item. Based on the pre-specified CVR cutpoint value, we eliminated all items 
except sleep, mood, and concentration in the HFI. Eliminated items were more frequently 
endorsed by participants’ as zero or no interference (22% to 37.9%) compared to the three 
retained items (2.2% to 18.1%).
Cronbach’s alphas are shown in Table 3. Alphas for the HFRDIS exceeded 0.92 for all time 
points and samples. Alphas for the HFI exceeded 0.82 for all time points and samples.
The confirmatory factor analyses suggested that a one-factor model of the HFRDIS fit the 
data well in the pooled sample as well as in each trial sample (see Table 4). Because the one-
factor model of the HFI was saturated (i.e., just identified with three indicators), all indices 
showed perfect fit in each sample. In addition, all items for both scales had large factor 
loadings.
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Correlations showing good convergent validity of the HFI are shown in Table 5. The HFI 
exhibited strong and positive associations with the HFRDIS (rho ≥0.907, p < 0.001). The 
pattern of correlations between the HFRDIS and diary and MENQOL was similar in 
direction, strength, and significance to the HFI and those outcomes.
Cutpoints
Additional associations are shown in Table 6. Cutpoints of mild (0 to 3.9), moderate (4 to 
6.9) and severe (7 to 10) on both the HFRDIS and HFI were significantly and positively 
associated with symptom measures. More hot flash interference reflected worse VMS diary 
frequency, severity and bother as well as worse PSQI sleep, insomnia severity, and anxiety. 
The associations supported the cutpoint values for both scales.
MIDs
Table 7 displays MID results for the HFRDIS and HFI. Overall, the average MID for the 
HFRDIS was 1.66 and for the HFI was 2.34.
DISCUSSION
Hot flash related daily interference is an important patient-reported outcome with the 
HFRDIS measure having been widely used internationally. This is the first report to evaluate 
a shortened version of the HFRDIS, to evaluate cutpoints, and establish MIDs for both the 
HFRDIS and condensed HFI. Data from the 10-item HFRDIS showed good fit to a single 
hot flash interference factor, suggesting that the single-factor conceptualization of the 3-item 
HFI was reasonable. The HFI had high internal consistency reliability (Cronbach’s alphas) 
and demonstrated strong construct and convergent validity (correlations). In addition, 
cutpoints for mild, moderate, and severe interference on both the HFRDIS and HFI were 
associated with VMS diary, sleep, and anxiety symptoms. Finally, we identified MIDs for 
the HFRDIS and HFI, which may be used in future power analyses to determine appropriate 
sample sizes for clinical trials and in interpreting responsiveness to change and sensitivity to 
clinical treatments and other intervention effects over time.
We did not find a single item that was adequate for measuring interference, despite this 
being a possibility at the start of our analyses. We did not make a priori assumptions 
regarding the number of items to be retained in the shortened version. Our analytic methods 
also did not preclude this possibility. Sloan et al.43 present an excellent discussion of the 
relative advantages of single item vs. multi item scales. Single-item scales are easy to 
administer, reduce response burden, and can be psychometrically sound with ability to 
demonstrate validity and change over time, including in response to treatment effects.43 
Multi-item scales can be useful for multidimensional latent constructs, can reduce 
measurement error, can be scored to handle missing item data, and can improve reliability, 
validity, responsiveness to change over time, and sensitivity to intervention effects.43 Our 
three-item HFI has the advantages of a multi-item scale and because of its very small 
number of items, also has other advantages similar to single item scales such as being easy 
to administer, with minimal response burden, and demonstrated reliability, validity, and 
responsiveness to intervention effects.
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The three retained HFI items received the highest ratings from experts and were the least 
likely to receive participant ratings of zero or no interference. The links between frequent, 
severe, or bothersome VMS and sleep problems,44, 45 mood problems,46–49 and 
concentration difficulties50, 51 have all been previously documented and are consistent with 
two previously published MsFLASH reports: MsFLASH trial participants’ symptom 
priorities52 and symptom clusters.53 In MsFLASH 02, a companion study was added and it 
required trial participants to complete a card sort task to indicate which three of twelve 
possible symptoms they would most like to alleviate.52 The four most highly rated 
symptoms were VMS, sleep disruption, concentration impairment, and fatigue. Mood was 
endorsed much less frequently in this analysis possibly because women with mood 
disturbances were excluded from the trial. Similarly, using pooled data across the MsFLASH 
trials (n=899), five classes of symptom clusters were found.53 The classes were: (1) hot flash 
interference, sleep problems, and pain, (2) hot flash interference, sleep problems, mood 
problems, and pain, (3) hot flash interference and sleep problems, (4) hot flash interference 
and mood problems, and (5) low severity of all symptoms. Problems with concentration 
were not measured as a MsFLASH outcome for use in the clusters analysis. In general, these 
studies substantiate the inclusion of sleep, mood, and concentration problems as the 
symptoms most closely associated with hot flashes or hot flash interference.
Published findings from one study support the exclusion of the ‘relationships with others’ 
item but not the interference with ‘work’ item.54 In an analysis of data from the Seattle 
Midlife Women’s Health study, multilevel modeling was used to test correlates of symptom 
interference. Interference with relationships and work were each measured with diary 
questions over time and 0 (not at all) to 6 (extremely or a lot) response options. Hot flash 
severity was measured over time and rated from 0 (not present) to 4 (extreme). Interference 
with relationships was not significantly associated with hot flash severity, but was associated 
with other variables including mood, sleep symptoms, and forgetfulness/difficulty 
concentrating. Interference with work was significantly associated with hot flash severity, 
depressed mood, difficulty getting to sleep, forgetfulness/difficulty concentrating, and other 
variables. Differences between our study and this published study might have been related to 
the longitudinal nature of the published study or differences between measurement tools. 
However, in both our study and this published study, hot flashes, sleep, and difficulty 
concentrating did cluster together.
The values we identified for the MIDs can be compared to another MID for a similarly 
scored symptom interference scale. Using pooled data from over 2000 patients with nerve 
pain from diabetic neuropathy or postherpetic neuralgia, a 1 to 2 point change on a 0 to 10 
point sleep interference mean score was found to be an appropriate MID.55 This MID range 
for sleep interference is very similar to our MIDs of 1.56 to 2.57 for hot flash interference.
Study findings should be considered in light of some limitations. First, although MsFLASH 
01 trial participants were diverse in terms of race/ethnicity, participants of the remaining two 
trials’ were less diverse. All participants were American and English speaking. Therefore, 
whether our findings will hold true if more diverse samples or translated versions of the 
scale are included remains to be determined. Second, MsFLASH trials excluded women 
with mood disturbances, which may have affected the results reported here. Third, we 
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acknowledge the data driven approach to establishing cutpoints as an alternative method that 
might have yielded different results.33–37 Fourth, MIDs can vary among different 
populations56 and additional studies may yield different findings.
Future research implications are based on study findings and limitations and include the 
following. It will be important to replicate our findings in other populations and using 
different translations of the HFRDIS to determine whether the 3-item solution and MIDs 
hold across populations, including those with mood disturbances, and across different 
instrument translations. While the three retained items for the HFI were those most relevant 
to this American sample, it is possible that different items or a different number of items 
might perform best in non-American or non-English speaking populations. It is also possible 
that MIDs may vary by population or with different translated versions. In addition, a future 
study could use a data-driven approach to establish severity-based cutpoints for hot flash 
interference. Methods could follow those outlined by Jeon et al.33 Using data from two 
studies involving cancer patients assessed at multiple time points, they used 16 different 
symptom severity ratings to evaluate cutpoints for the corresponding 16 different symptom 
interference ratings. Interference cutpoints varied across the 16 symptoms. The most 
common cutpoints (4 symptoms, 25%) followed the categories we used (1-3, 4-6, and 7-10) 
and the second most common cutpoints (3 symptoms, 19%) used categories of 1, 2-4, and 
5-10. All other symptoms used different combinations of cutpoints. We encourage additional 
analyses by other investigators and clinicians who have used the HFRDIS.
CONCLUSION
In conclusion, we successfully created a shorter HFI scale that will be useful in busy clinical 
practices to effectively monitor hot flash interference and response to treatment over time. 
Moreover, our findings may help research studies where response burden may be an issue. 
The scale cutpoints and MIDs for the HFRDIS and HFI should prove useful in interpreting 
the existing as well as future research. We urge clinicians and researchers to consider 
assessing hot flash interference in midlife women as an important patient-reported outcome 
and to conduct similar psychometric analyses using existing data from more diverse 
populations and/or with translated versions of the HFRDIS.
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Table 1
Baseline Demographic and Clinical Characteristics of the three MsFLASH Trials
MsFLASH 01 MsFLASH 02 MsFLASH 03
(n=205) (n=355) (n=339)
n (%) n (%) n (%) p
Age at screening, median (IQR) 54.0 (51.0, 57.0) 54.0 (52.0, 57.0) 54.0 (52.0, 57.0) 0.062
 <50 24 (11.7) 19 (5.4) 30 (8.8) 0.189
 50-54 95 (46.3) 162 (45.6) 147 (43.4)
 55-59 66 (32.2) 130 (36.6) 123 (36.3)
 ≥60 20 (9.8) 44 (12.4) 39 (11.5)
Ethnicity <0.001
 African-American 89 (43.4) 88 (24.9) 111 (32.8)
 White 99 (48.3) 228 (64.6) 203 (60.1)
 Other 17 (8.3) 37 (10.5) 24 (7.1)
Education <0.001
 ≤High school diploma or GED 38 (18.5) 21 (5.9) 55 (16.3)
 Post-high school 87 (42.4) 112 (31.6) 111 (32.8)
 College graduate 80 (39.0) 221 (62.4) 172 (50.9)
Smoking <0.001
 Never 99 (48.3) 233 (65.8) 175 (51.9)
 Past 59 (28.8) 89 (25.1) 107 (31.8)
 Current 47 (22.9) 32 (9.0) 55 (16.3)
Body mass index, median (IQR) 28.3 (24.5, 32.2) 26.9 (23.6, 29.9) 27.0 (23.7, 31.2) 0.007
 <25 54 (26.5) 123 (34.6) 118 (35.5) 0.005
 25-29.9 72 (35.3) 144 (40.6) 107 (32.2)
 ≥30 78 (38.2) 88 (24.8) 107 (32.2)
Menopause status 0.27
 Postmenopausal 142 (69) 266 (75) 256 (76)
 Perimenopausal 41 (20) 65 (18) 52 (15)
 Indeterminate 22 (11) 24 (7) 31 (9)
Clinical Site <0.001
 Boston 43 (21.0) 0 (0.0) 100 (29.5)
 Indianapolis 35 (17.1) 118 (33.2) 0 (0.0)
 Oakland 57 (27.8) 110 (31.0) 0 (0.0)
 Philadelphia 70 (34.1) 0 (0.0) 121 (35.7)
 Seattle 0 (0.0) 127 (35.8) 118 (34.8)
VMSa per day, median (IQR)
 Frequency 8.4 (6.4, 11.1) 6.9 (4.9, 9.9) 6.5 (4.9, 9.8) <0.001
 Severity 1.1 (0.8, 1.5) 1.0 (0.7, 1.3) 1.0 (0.7, 1.3) <0.001
 Botherb 2.1 (1.8, 2.5) 2.0 (1.6, 2.3) 2.0 (1.6, 2.3) <0.001
HFRDIS, median (IQR) 3.5 (2.0, 5.3) 2.7 (1.5, 4.9) 2.9 (1.7, 5.2) 0.037
IQR, interquartile range.
Menopause. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Carpenter et al. Page 16
aVMS, vasomotor symptoms, VMS severity was measured from 0 (mild), 1 (moderate) or 2 (severe).
bVMS bother was measured from 0 (not at all), 1 (a little), 2 (moderately), or 3 (a lot).
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Table 2
MsFLASH Experts’ Content Validity Ratios (CVRs) and MsFLASH Participants’ HFRDIS Item Distributions
MsFLASH Experts MsFLASH Participants (n=899)
CVRsa (n=7) n (%) Endorsing Zero (No) Interferenceb Median (IQR)
Work −0.143 242 (27.3) 2.0 (0.0, 4.0)
Social activities −0.429 311 (34.8) 1.0 (0.0, 3.0)
Leisure activities −1.000 274 (30.8) 1.0 (0.0, 4.0)
Sleepc 1.000   20 (2.2) 5.0 (2.0, 8.0)
Moodc 1.000 157 (17.6) 2.0 (0.0, 5.0)
Concentrationc 0.714 161 (18.1) 2.0 (0.0, 5.0)
Relations with others −0.143 337 (37.9) 1.0 (0.0, 3.0)
Sexuality −0.143 288 (32.8) 1.0 (0.0, 5.0)
Enjoyment of life 0.429 221 (24.8) 2.0 (0.0, 4.0)
Life satisfaction 0.429 196 (22.0) 2.0 (0.0, 4.0)
aCVR, content validity ratio, cutpoint of 0.622 was used to identify items to retain in HFI.
bActual and possible range for all items was 0 (no) to 10 (completely) interference.
c
Item was retained in the short scale.
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Table 3
HFRDIS and HFI Cronbach’s Alpha Coefficients by Study Population and Time Points
Combined Sample
(n=899)
MsFLASH 01
(n=205)
MsFLASH 02
(n=355)
MsFLASH 03
(n=339)
HFRDIS
 Baseline 0.932 0.938 0.929 0.930
 Post-randomization 0.942 0.945 0.945 0.927
HFI
 Baseline 0.830 0.827 0.837 0.823
 Post-randomization 0.856 0.859 0.830 0.882
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Table 4
HFRDIS Confirmatory Factor Analyses Fit Indices by Study Population
Combined Sample
(n=899)
MsFLASH 01
(n=205)
MsFLASH 02
(n=355)
MsFLASH 03
(n=339)
HFRDIS
 Comparative Fit Index 0.988 0.989 0.987 0.986
 Tucker-Lewis Index 0.985 0.986 0.983 0.983
 SRMRa 0.061 0.057 0.066 0.063
aSRMR, Standardized Root Mean Square Residual.
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Table 5
Spearman’s Rank Correlation Coefficients among HFRDIS, HFI, and Other VMS Measures
HFRDIS HFI
Baseline Post-randomization Baseline Post-randomization
HFRDISa 1 0.944* 0.907* 1
HFIb 0.907* 1 1 0.944*
VMSc frequency 0.179* 0.287* 0.183* 0.299*
 Daytime 0.132* 0.480* 0.118* 0.504*
 Nighttime 0.218* 0.479* 0.243* 0.465*
VMSc severity 0.369* 0.469* 0.363* 0.471*
 Daytime 0.345* 0.437* 0.309* 0.466*
 Nighttime 0.333* 0.448* 0.354* 0.438*
VMSc bother 0.397* 0.485* 0.401* 0.483*
 Daytime 0.368* 0.439* 0.342* 0.480*
 Nighttime 0.360* 0.454* 0.392* 0.445*
MENQOLd 0.546* 0.588* 0.540* 0.582*
*p-value < 0.001.
a
HFRDIS, Hot Flash Related Daily Interference Scale.
b
HFI, Hot Flash Interference scale.
cVMS, vasomotor symptoms.
d
MENQOL, Menopausal Quality of Life Scale.
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Table 7
Minimally Important Differences (MID) for HFRDIS and HFI Scores
N (%) HFRDISa MID
Mean (SD)
HFIb MID
Mean (SD)
40%-60% reduction in total VMSc frequency 153 (17.35) −1.76 (1.97) −2.57 (2.29)
40%-60% reduction in daytime VMS frequency 132 (14.97) −1.58 (1.67) −2.24 (2.33)
40%-60% reduction in nighttime VMS frequency 112 (12.70) −1.76 (1.90) −2.38 (2.19)
0.5-1.5 reduction in total MENQOLd score 291 (32.99) −1.60 (1.85) −2.26 (2.24)
Average of all of the column MIDs −1.66 −2.34
a
HFRDIS, Hot Flash Related Daily Interference Scale.
b
HFI, Hot Flash Interference scale.
cVMS, vasomotor symptoms.
d
MENQOL, Menopausal Quality of Life Scale.
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